Praxis Administrative Spending Reaches $42.7 Million As It Prepares For Potential Drug Launches

The relutrigine team is fully hired, with FDA decisions targeted for December and January.

Share
Praxis Administrative Spending Reaches $42.7 Million As It Prepares For Potential Drug Launches

Praxis Precision Medicines, which develops drugs for epilepsy and movement disorders, reported third-quarter administrative spending of $42.7 million, compared with $12.6 million a year earlier, as it prepares for potential drug launches. Its Monday quarterly update, accompanying an SEC filing, put the net loss at $94.2 million versus $73.9 million a year earlier.

Personnel And Professional Costs Rise

Personnel expenses accounted for $17.2 million of the $30.1 million increase in administrative costs. Professional expenses added $9.4 million, while other expenses contributed $3.5 million, according to the company's quarterly results.

Research spending moved in the opposite direction, reaching $64.2 million against $65.8 million a year earlier. Cerebrum platform expenses fell $8.8 million, partly offset by a $7.0 million increase in personnel costs. The quarter's net loss included $14.9 million in stock-based compensation, compared with $7.4 million a year earlier.

Praxis held approximately $1.3 billion in cash and investments on September 30, 2026, versus $926.1 million at year-end 2025. The company attributed the increase primarily to its January 2026 follow-on offering and investment interest, partly offset by operating cash use, and expects those resources to support operations into 2028.

Launch Teams Await FDA Decisions

The FDA is reviewing relutrigine for severe developmental epilepsies associated with the SCN2A and SCN8A genes, with a target decision date of December 27, 2026. Ulixacaltamide, its essential-tremor treatment, has a January 29, 2027, target date; neither review is an approval.

“The relutrigine team is fully hired, and we expect the ulixacaltamide sales force to be in place this quarter,” said Marcio Souza, president and chief executive officer of Praxis.

Essential tremor affects approximately seven million U.S. patients, the company said. Ulixacaltamide received FDA Breakthrough Therapy Designation in December 2025. Praxis began a patch-development collaboration with Remagine Labs in July 2026 to broaden potential treatment options, and has restarted its long-term safety study for eligible patients ahead of possible commercial availability.

Epilepsy Trials Extend Beyond Launches

Praxis also expects results in the fourth quarter of 2026 from its relutrigine trial in a broader population with developmental epilepsies. Enrollment continues in the elsunersen trial for early-onset SCN2A epilepsy, with results anticipated in 2027.

The company restarted vormatrigine's seizure trial with design changes drawn from an earlier study. Praxis is also reviewing the design of a planned trial testing vormatrigine as a stand-alone treatment and expects to initiate it in 2027.

Those programs span Praxis' drug-development platforms: Cerebrum produces oral medicines, while Solidus develops medicines designed to alter gene expression. Elsunersen belongs to the latter platform; vormatrigine targets common epilepsies, which affect an estimated 3.5 million people in the U.S.

Management plans to discuss commercial strategy, launch readiness and its development pipeline at Thursday's Investor Day.

Sources